Unexpected Primaquine‐Induced Hemolysis in a <scp>G6PD</scp> ‐Normal Patient: A Case Report From Nepal

Primaquine, an antimalarial drug, is essential for preventing relapses of <i>Plasmodium vivax</i>. However, it poses a risk of hemolytic anemia, particularly in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. This case report details a 27-year-old male with normal G6PD levels who developed hemolytic anemia following primaquine therapy for <i>P. vivax</i> malaria. Despite a normal quantitative G6PD analysis, the patient experienced a significant drop in hemoglobin, necessitating early discontinuation of the drug. This case highlights the potential for hemolysis in G6PD-normal patients, underscoring the importance of close monitoring and the limitations of current G6PD screening methods.